Anti-dsDNA antibodies are characteristic of systemic lupus erythematosus (SLE) and appear to be critical in the pathogenesis of tissue injury. There is a good correlation between anti-dsDNA antibody levels and disease activity. The overall detection rate of these antibodies is approximately 50-55% in SLE patients and about 89% in SLE patients with active renal disease. When they are present in high concentration, anti-dsDNA antibodies are virtually specific for SLE (>90%). Antibodies to dsDNA may disappear with immunosuppressive treatment and during remission. They rarely occur in other autoimmune disorders. Signosis has developed anti-dsDNA ELISA, a sandwich quantitative assay, to screen for the presence of serum ds-DNA antibodies IgG.
Sample type: serum, plasma, cell culture supernatants and urine
Assay range: 4 ng/ml to 125ng/ml
Autoimmune ELISA kits measure autoimmune antibodies in the serum. It is based on the principle of a solid phase enzyme-linked immunosorbent assay. The assay utilizes a specific antigen for immobilization on the microtiter wells and anti-human IgG antibody conjugated to horseradish peroxidase (HRP) for detection. The test sample is allowed to react simultaneously with the two components, resulting in autoimmune antibodies being sandwiched between the solid phase antigen and the enzyme-linked antibodies. After incubation, the wells are washed to remove unbound antibodies. Then an HRP substrate is added to develop a blue color. The color development is stopped with the addition of Stop Solution changing the color to yellow. The concentration of autoimmune antibodies is directly proportional to the color intensity of the test sample. Absorbance is measured spectrophotometrically at 450 nm.
LiteratureView user manual
STAT3 Signaling in B Cells Is Critical for Germinal Center Maintenance and Contributes to the Pathogenesis of Murine Models of Lupus. C Ding, X Chen, P Dascani, X Hu, R Bolli, H Zhang, The Journal of Immunology, 2016. Published online before print April 25, 2016, doi: 10.4049/jimmunol.1502043.
Irgm1 coordinately regulates autoimmunity and host defense at select mucosal surfaces. Azzam, Kathleen M., et al. JCI Insight, vol. 2, no. 16, 2017, doi:10.1172/jci.insight.91914.